NCT00440427已完成1 期
A Randomized, Open-Label, Single-Dose Parallel Group Study of the Pharmacokinetic Profile, Safety, and Tolerability of 25- and 50-mg Desvenlafaxine Sustained Release (DVS SR) in Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2007年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Safety
研究概览
简要总结
To assess the initial pharmacokinetic profile of single doses of 25mg and 50 mg of DVS SR to healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or non-pregnant, non-lactating women
- •Body mass index 18 - 30 kg/m2
- •Body weight greater than or equal to 60kg
排除标准
- 未提供
结局指标
主要结局
Safety
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)Depression - Major Depressive DisorderNCT01190514Pfizer41
已完成
3 期
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal WomenVasomotor SystemMenopauseNCT00369434Wyeth is now a wholly owned subsidiary of Pfizer450
已完成
3 期
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive DisorderDepressive Disorder, MajorNCT00384033Pfizer638
已完成
1 期
Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy SubjectsRenal Insufficiency, ChronicHealthyHepatic InsufficiencyNCT00805090Javelin Pharmaceuticals37
Unknown
1 期
Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers (III)HealthyNCT04185805Daewoong Pharmaceutical Co. LTD.24